They concluded that combining novel CAR-T cell therapy with the HGF receptor-neutralizing antibody Rilotumumab (AMG102) could enhance therapeutic efficacy, not only in Ewing sarcoma (EWS) but also in tumors with an abnormal activation of the HGF/c-MET pathway [118]. The gene discussed is MET; the disease is Ewing sarcoma.